'Mergers & Acquisitions'
| Piramal Health Acquires Bayer Pharma’s Molecular Imaging Portfolio|
| Piramal Healthcare Ltd has acquired the molecular imaging development portfolio of Bayer Pharma AG for an undisclosed sum.|
It has signed an agreement to acquire the worldwide rights to the molecular imaging research and development portfolio of Bayer through its newly created subsidiary – Piramal Imaging SA, a note from Piramal Healthcare said.
The portfolio includes rights to florbetaben, that helps detect beta-Amyloid plaque deposition in the brain – an indication of probable Alzheimer’s disease.
Detection of beta-Amyloid depositions is expected to result in earlier diagnosis and more specific treatment of Alzheimer’s disease, the company said.
Florbetaben is undergoing final stages of Phase III clinical trials. These final stage trials have shown that PET imaging with florbetaben reliably detects beta-amyloid in the brain with accuracy and so could be a potential tool to aid the diagnosis and assessment of Alzheimer’s disease, the company said.
Piramal Healthcare recently received the European CE regulatory approval for an innovative bio-orthopaedic product for cartilage repair, BST-CarGel, acquired from the Biosyntech stable. The development enables the company to commercialise BST-CarGel in all countries in the European Union, he added.
In the latest Bayer agreement, Piramal will have the intellectual property (including patents, trademarks and know-how), worldwide development, marketing and distribution rights of the lead compound florbetaben as well as other clinical and pre-clinical assets of Bayer’s molecular imaging business.
Further, core members of Bayer’s research and development team working on the portfolio will be joining Piramal Imaging, which will carry forward the development of florbetaben and take it through regulatory approval processes worldwide. Piramal is planning to file for regulatory approvals in 2012.
| Daiichi Sankyo & GSK Set Up a New Vaccine JV in Japan|
| Pharma majors GlaxoSmithKline and Daiichi Sankyo have announced a strategic alliance and formed a vaccine Joint Venture, named Japan Vaccine.|
The JV is responsible for development and commercial rights of prophylactic vaccines.
The companies will invest equally in the JV and the transaction is expected to be completed in third quarter 2012, subject to local regulatory approvals.
Japan Vaccine will contribute to improving access to vaccines in Japan, introduce new vaccines, and bring together the technologies and products of parent companies to create more convenient combination vaccines.
The new JV will provide evidence based information and ensure stable supply of vaccines, the companies said.